About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  About Us
  Research & Development
  Branded Formulations
  Financial Results
  - FY17 Results
  - Investor Presentation
  - Chairman's Speech 2017
  - Annual Reports
  Facilities Virtual Tour
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2017

Annual Report 2017

  Biocon Academy



Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics.

We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including Monoclonal Antibodies (MAbs), rh-insulin and Insulin Analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world's fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country.


Kiran Mazumdar-Shaw speaks to CNBC-TV18 on Status of EMA Dossiers


Regulatory processes for biosimilars & new biologics are extremely complex, not comparable to generics.

Biocon sought withdrawal of biosimilar Trastuzumab & Pegfilgrastim dossiers; will resubmit post re-EMA inspection.

The request for withdrawal of the dossiers and re-submission is part of the EMA procedural requirements linked to this re-inspection and will be considered by the EMA´s Committee for Medicinal Products for Human Use (CHMP)

Biocon on track to complete CAPA by end Q2. Will seek re-inspection of drug product facility in Q3.

(Video Credit: CNBC TV 18)

Biocon Q1FY18 Performance Highlights by Kiran Mazumdar-Shaw, CMD, Biocon  


Kiran Mazumdar-Shaw discusses Financial Performance and Highlights of Biocon's Q1FY18.

Biocon: Engaged in Affordable
Innovation for Global Impact
Stock Update

  Company Announcements  

Aug. 16, 2017 
 Company Statement on  status of EMA Dossiers

Jul. 31, 2017 
 Company Statement on  USFDA Visit in  May/June2017. CAPA is  under Implementation

Jul. 27, 2017 
 Biocon Reports Q1FY18  Revenue at Rs 988 Crore;  EBITDA at Rs 246 Crore;  Net Profit at Rs 81 Crore

Jul. 14, 2017 
 FDA Oncologic Drugs  Advisory Committee  Unanimously  Recommends  Approval of Mylan and  Biocon’s Proposed  Biosimilar Trastuzumab



Biocon Malaysia

  Media Coverage  

 July 2017:  It's Biocon's day  in the sun.

 July 2017:  US FDA Panel  Nod for Biocon  Breast  Cancer Drug  Biosimilar.








Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2016, Biocon. All Rights Reserved